Dergiler / Haydarpaşa Numune Medical Journal / 2020 / Cilt: 60 - Sayı: 4

Comparison of The Treatment Efficacy of Montelukast and Zafirlukast in Children with Asthma

Sayfa
329–334
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Discussion and Conclusion: It was found that monteluksat and zafirlukast were effective in asthma treatment and there was no difference between their effects.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide.
📊
Temel Bulgular & Veri:Methods: Sixty-one patients diagnosed with asthma in the age group of 6-14 years were included in the study.
💡
Sonuç & Katkı:Discussion and Conclusion: It was found that monteluksat and zafirlukast were effective in asthma treatment and there was no difference between their effects.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Introduction: Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Leukotriene antagonists have long been used in the treatment of asthma. This study was conducted to compare the effectiveness of the montelukast and zafirlukast treatment in children diagnosed with asthma. Methods: Sixty-one patients diagnosed with asthma in the age group of 6-14 years were included in the study. Patients were consecutively divided into 2 groups, and the first group was given 5 mg of montelukast before sleep and the second group received 10 mg/day of zafirlukast in two doses. The patients were followed up monthly for 6 months. Short acting beta agonist and inhaled corticosteroid use, daytime symptoms, night awakenings, admission to the emergency department andFEV1 value were compared before and after the treatment and between two groups. Results: Significant improvement was observed in both groups during post-treatment period when compared to the pre-treatment period in terms of the short acting beta agonist and inhaled corticosteroid use, daytime symptoms, night awakenings, mean FEV I. However, no statistical difference was determined between two groups. Discussion and Conclusion: It was found that monteluksat and zafirlukast were effective in asthma treatment and there was no difference between their effects.

🔖

Bu Makaleye Atıf Yap

VOLKAN, B., ÖKTEM, S., BORAN, P., TOKUÇ, G. (2020). Comparison of The Treatment Efficacy of Montelukast and Zafirlukast in Children with Asthma. Haydarpaşa Numune Medical Journal, Cilt: 60 - Sayı: 4, 329–334. https://ajindex.com/articles/165923

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Tomaç N, Saraçlar Y.; Astım epidemiyolojisi. Klinik Çocuk Forumu Pediatrik Allerji Özel Sayısı 2 2003;3: 6-16
  2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (Update 2015)
  3. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999;130:487–95
  4. Chauhan BF, Jeyaraman MM, Singh Mann A, Lys J, Abou-Setta AM, Zarychanski R, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev 2017;3:CD010347
  5. Gayret ÖB, Öktem S, Tokuç AG.; Astımlı Çocuklarda Lökotrien Reseptör Antagonist ile İnhale Kortikosteroid Etkinliğinin Karşılaştırılması. Çocuk Dergisi 2018;18:24–8
  6. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147–52
  7. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronicasthma. Montelukast Asthma Study Group. Eur Respir J 1998;11:1232–9
  8. Silverman RA, Nowak RM, Korenblat PE, Skobeloff E, Chen Y, Bonuccelli CM, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004;126:1480–9
  9. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med 2010;103:98–106
  10. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48
  11. Claesson HE, Dahlén SE. Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J Intern Med 1999;245:205–27
  12. Nathan RA, Bernstein JA, Bielory L, Bonuccelli CM, Calhoun WJ, Galant SP, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998;102:935–42
  13. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: a 13- week multicenter study. The Zafirlukast Trialists Group. Cli